Table 3. Inhibition of PEL lytic activity by FasL transfected cells.
| % 51Cr release at E:T | |||||
|---|---|---|---|---|---|
| Effector | Pre-incubated with | Target | 10:1 | 5:1 | SR |
| B/6 anti-L1210 | alone | L1210 | nm | 41·6 | 11·2 |
| B/6 anti-L1210 | +NIH3T3.FasL (1:0·4) | L1210 | nm | 4·7 | 11·2 |
| B/6 anti-L1210 | +NIH3T3 (1:0·4) | L1210 | nm | 56·2 | 11·2 |
| B/6 anti-EL4 | alone | EL4 | 35·4 | 20·0 | 6·3 |
| B/6 anti-EL4 | +NIH3T3.FasL (1:0·2) | EL4 | 10·7 | 7·2 | 6·3 |
| B/6 anti-EL4 | +NIH3T3 (1:0·2) | EL4 | 36·0 | 18·0 | 6·3 |
| B/6 anti-EL4 | +BW.FasL (1:1) | EL4 | 17·8 | 11·1 | 6·3 |
| B/6 anti-EL4 | +BW.Vector (1:1) | EL4 | 35·0 | 22·4 | 6·3 |
Allogeneic B/6 anti-L1210 (b anti-d) or syngeneic B/6 anti-EL4 (b anti-b′) PEL-CTL were preincubated with NIH3T3, NIH3T3.FasL, BW.FasL or BW.Vector for 16 hr before adding
51
Cr-labelled indicator targerts (3 × 10 4 cells/well). Lysis was assessed after 3 hr. Ratio of effector PEL to their partners during preincubation is indicated in parenthesis.
nm, not measured.